Latest Biogen News & Updates

See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Biogen

Biotechnology company developing medicines for neurological, immunological, and rare diseases

biogen.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 7,900–10,000
Industry: Pharmaceuticals

Last updated October 28

Latest news about Biogen

In short: Biogen beat third-quarter expectations, raised its outlook and advanced Alzheimer’s and lupus programs.

Company announcements

October 15 Biogen

Biogen expects a $284 million charge in Q3 2026 results

The pre-tax charge stems from acquired in-process research and development expenses, impacting net income per diluted share by approximately $1.65 to $1.70.

August 6 Biogen

Biogen completes acquisition of RayThera Inc

The deal adds multiple potential assets for immune-mediated diseases, including a lead program in Phase 1 development, growing Biogen's immunology portfolio.

August 3 Biogen

Biogen welcomes Michael Parini as Chief Legal Officer

He brings over 20 years of legal and strategic leadership in healthcare. He will help execute Biogen's strategy and build its future.

July 29 Biogen

Biogen reports second quarter 2026 revenue of $2.7 billion

Growth portfolio increased 24% year-over-year. The company updated full-year guidance and announced the completed Apellis acquisition.

Media coverage

October 28 MLex

Biogen reveals Dutch antitrust probe of Stratify test

US biotechnology company Biogen is being probed by the Dutch competition authority in relation to its sclerosis-linked test Stratify, the company said in a regulatory...

October 28 The Globe and Mail

Biogen (NASDAQ:BIIB) delivers impressive Q3 2026

Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 2026, with revenue up 10.6% year on year to ...

October 28 BioSpace

Biogen CEO Says Company Can Grow Without Mergers and Acquisitions

Third-quarter revenue rises as Biogen CEO Chris Viehbacher states the firm can grow its bottom line using existing products and late-stage pipeline assets without relying on new acquisitions.

October 27 The Wall Street Journal

Biogen Swings to Loss, Logs Higher Sales

The biotechnology company said the swing to a loss was primarily due to transaction-related charges.

Never miss news about Biogen

Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Biogen competitors & trending companies

Browse news for competitors to Biogen and other trending companies.